Tuesday, June 19th, 2018 | w San francisco
8:00AM–9:00AM: Breakfast & Networking
9:00AM-9:35AM: Opening Remarks
9:35AM-10:10AM: Fact Or Fiction: What Algorithms Will Do For Healthcare (And When)
While the singularity is nowhere in sight, we are inching ever closer to a world in which more jobs are being replaced or augmented by machines. Industry sentiment ranges from praise to skepticism—some in healthcare are bullishly telling medical students to avoid radiology altogether while others are questioning the level of validation pursued by AI/ML companies. In this session, leaders will take the stage to voice their views on these divergent paths in the AI space.
Robert Wachter, MD, Professor and Chair of the Department of Medicine at UCSF
Vineeta Agarwala, MD, PhD, Venture Partner at Google Ventures
10:10AM-10:50AM: Is AI Ready For Its Bedside Debut?
A bounty of new studies suggests machine learning algorithms are more effective at diagnosis than physicians are, but machines are not diagnosing real patients—yet. Providers are fairly asking some tough questions of these tools as they relate to care delivery—are they effective, will I get paid, and does this put me at greater risk for malpractice? We’ll discuss these implementation hurdles and lay out the timeline for today’s solutions to fully realize the opportunity they represent for patients and providers—lower costs, faster service, and better treatment.
Fabien Beckers, PhD, CEO & Co-founder of Arterys
Tod Davis, Associate Director for Data Science at Cedars-Sinai
Aashima Gupta, Global Head - Healthcare Solutions at Google Cloud Platform at Google
Sameer Badlani, MD, Chief Health Information Officer & VP at Sutter Health
11:00AM-11:40AM: AI Has The Power To Turn Pharma On Its Head—But Will It?
Everyone is talking about AI/ML’s potential for drug discovery, clinical trial management, and precision medicine. What’s less clear is how—and to what degree—these advancements will have ripple effects across the industry and for patients. Will pharma bend the healthcare cost curve? Which beyond the pill solutions will they embrace? We’ll explore just how big of an impact AI/ML use cases are having on pharma’s current business models—and what could be upended altogether.
John M. Baldoni, Senior Vice President, In silico Drug Discovery at GSK Pharma R&D
Iya Khalil, Co-founder, Chief Commercial Officer & EVP of GNS Healthcare
Bruce Palsulich, Vice President of Product Strategy at Oracle Health Sciences Global Business Unit
John Piccone, Principal at ZS Associates
Rebecca Robbins, Business Reporter at STAT News
11:40AM-12:20PM: Exploring The Inherent Tensions Of AI In Health With IDEO. Where Do You Stand?
Coffee or tea? Black/white or grey? Transparency or privacy? In this exercise, we’ll explore provocative “this or that” questions together by physically moving around the room to show, quite literally, where we stand on each tension. Along the way, we’ll discover each other’s beliefs, hopes, and fears as they relate to AI in health, and come to better understand the unique perspective we bring to the table, too.
1:20PM-2:00PM: Emerging Ethical Issues For Healthcare In The Age Of AI
Despite all their promise, algorithms trained on data which itself may contain unforeseen omissions or biases can result in subtly—and perhaps dangerously—biased predictions. In this session, experts will open a discussion around how to approach a framework for addressing unresolved ethical issues as a community. We’ll explore the specific ethical issues algorithms pose, including: what margin of error will be allowed for computers in healthcare and what rights do patients have with regards to the data and algorithms involved in their care?
Ian Blumenfeld, Chief Data Scientist at Clover Health
Kirsten Ostherr, Professor of Digital Health & Media Studies at Rice University
Hanne Tidnam, Editorial Partner at Andreessen Horowitz
2:00PM-2:40PM: Forging Partnerships For Impact Across Academia, Startups, And Enterprise
With many of the brightest machine learning minds in academia, how can breakthrough algorithms and applications translate into real business value for startups and enterprise organizations? This panel will explore the opportunities for academics and industry leaders to form critical partnerships, share access to data sets, and accelerate validation.
Brandon Ballinger, Co-founder of Cardiogram
Gunnar Carlsson, Co-founder & President of Ayasdi
Marta Gaia Zanchi, Founding Director of Stanford Byers Center for Biodesign
Karley Yoder, Director of Product Management, Artificial Intelligence at GE Healthcare
2:45PM-3:25PM: How Enterprise Can Prepare For An AI-First World
Clinical AI/ML applications have the potential to create massive savings to the US healthcare system, but it’s not as simple as flipping the “AI on-switch.” How can enterprises evaluate their readiness to embed AI/ML solutions into their business lines? Enterprise leaders will offer deep insight into (1) the key indicators that a company is (or isn’t) ready to enter into a pilot or full commercial contract with an AI/ML startup, (2) the internal collaborations and communication channels that need to be established and how, and (3) how to be an acquirer that continues to spur—and avoid killing—the innovation in an AI/ML startup acquisition.
Kay Eron, Vice President & General Manager at Philips Neuro
Sanji Fernando, Vice President & Head of OptumLabs Center for Applied Data Science
Todd Pierce, Member Board of Directors at Dignity Health & Rock Health
Megan Zweig, Director of Research at Rock Health
3:25PM-4:05PM: The Enterprise Playbook For Identifying Breakthrough Innovation
It has never been more crucial for enterprise to identify which startups are both optimally using AI/ML and ready to scale within healthcare. Yet the path forward for effective integration between startup technology and enterprise business lines is overwhelming—leaders must decide which type of contract is most helpful in managing “readiness risk,” disentangle the different validation signals—from the FDA to academic studies— to assess a startup’s potential to scale, and evaluate compatibility with their own internal data stack and workflows. Investors and enterprise leaders will discuss how companies should navigate the AI/ML startup space in order to differentiate between hype and real business value.
Rowan Chapman, Head of Johnson & Johnson Innovation, California
Christine Lemke, Co-founder & President of Evidation Health
David Rhew, MD, Chief Medical Officer & VP and GM of Enterprise Healthcare of Samsung
Bill Evans, CEO & Managing Director of Rock Health
4:15PM-4:45PM: Fireside Chat With Vinod Khosla
Vinod Khosla, a self-proclaimed “technology optimist” and prominent entrepreneur-turned-venture capitalist, has hardly been one to keep his thoughts on algorithms and healthcare to himself. His views on technology’s role in transforming the human aspect of medicine have sparked responses across the industry—especially from physicians themselves. We’ll sit down with Vinod to delve into how he evaluates the AI/ML healthcare startup space as an investor, his advice to enterprise leaders to stay nimble and innovative, and what he views to be the biggest promises of AI/ML in healthcare.
Vinod Khosla, Founder of Khosla Ventures
Christine Cassel, MD, Visiting Professor at UCSF
4:45PM-5:00PM: Closing Remarks
5:00PM-7:00PM: Networking Reception